Brief: Palvella Therapeutics Strengthens Leadership With Appointment Of Accomplished Scientist And Biopharmaceutical Executive David W. Osborne, Ph.D. As Chief Innovation Officer
03/09/2025 13:31
Sept 3 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O: PALVELLA THERAPEUTICS STRENGTHENS LEADERSHIP WITH APPOINTMENT OF ACCOMPLISHED SCIENTIST AND BIOPHARMACEUTICAL EXECUTIVE DAVID W. OSBORNE, PH.D. AS CHIEF INNOVATION OFFICER Source text: ID:nGNX7zqn0P Further company coverage: ARQT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs